• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本药品和医疗器械局监管科学研究在药物研发中的作用。

The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.

作者信息

Asahina Yasuko, Tanaka Ayumi, Uyama Yoshiaki, Kuramochi Kenji, Maruyama Hiroshi

机构信息

1 Regulatory Science Research Division, Office of Regulatory Science, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.

2 Office of Regulatory Science, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.

出版信息

Ther Innov Regul Sci. 2013 Jan;47(1):19-22. doi: 10.1177/2168479012469950.

DOI:10.1177/2168479012469950
PMID:30227480
Abstract

Recently, it is becoming increasingly difficult to develop innovative drugs. Thus, the role of regulatory science research in drug development and postmarketing settings has become more important. In this article, the authors discuss the roles of regulatory science research at the Pharmaceuticals and Medical Devices Agency (PMDA), which aims to improve public health in Japan.

摘要

近年来,开发创新药物变得越来越困难。因此,监管科学研究在药物研发和上市后阶段的作用变得更加重要。在本文中,作者讨论了药品和医疗器械管理局(PMDA)的监管科学研究的作用,该机构旨在改善日本公众的健康状况。

相似文献

1
The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.日本药品和医疗器械局监管科学研究在药物研发中的作用。
Ther Innov Regul Sci. 2013 Jan;47(1):19-22. doi: 10.1177/2168479012469950.
2
Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan.药品上市后全病例监测作为日本一项安全措施的有效性。
Ther Adv Drug Saf. 2021 Dec 16;12:20420986211065215. doi: 10.1177/20420986211065215. eCollection 2021.
3
The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.药品和医疗器械局及医疗保健专业人员在上市后安全性方面的作用。
Clin J Gastroenterol. 2014 Apr;7(2):103-7. doi: 10.1007/s12328-014-0474-6. Epub 2014 Mar 22.
4
[Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].[日本新药及医疗器械的研发与评估——监管机构的立场]
Brain Nerve. 2010 Mar;62(3):263-8.
5
Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.对日本《药品、医疗器械及其他治疗产品法》的考量与期望。
Regen Ther. 2015 May 15;1:80-83. doi: 10.1016/j.reth.2015.04.001. eCollection 2015 Jun.
6
Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.加速日本阿尔茨海默病药物研发的监管科学举措
Clin Ther. 2015 Aug;37(8):1622-6. doi: 10.1016/j.clinthera.2015.04.014.
7
[Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].[药品和医疗器械局(PMDA)关于研发(R&D)战略的药品事务咨询新行动]
Yakugaku Zasshi. 2013;133(2):183-6. doi: 10.1248/yakushi.12-00246-1.
8
[Regulatory Science in the Review of Drugs and Medical Devices].[药品和医疗器械审评中的监管科学]
Yakugaku Zasshi. 2016;136(4):557-62. doi: 10.1248/yakushi.15-00224-6.
9
Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.日本、欧盟和美国抗癌药物的监管审批途径。
Int J Hematol. 2016 Jul;104(1):73-84. doi: 10.1007/s12185-016-2001-7. Epub 2016 Apr 15.
10
Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDA's perspective.未来与前沿新兴技术相关的人工器官的发展及其监管评估:PMDA 的观点。
J Artif Organs. 2020 Sep;23(3):203-206. doi: 10.1007/s10047-020-01161-4. Epub 2020 Feb 28.